Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
The Lancet. Oncology|February 5, 2020
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trialJohn A Bridgewater, Siân A Pugh, Tom Maishman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 21, 2026
Personalising radiotherapy dose in anal cancer (PLATO) Platform: 6-month patient reported outcomes across ACT3, ACT4 and ACT5 trialsAlexandra Gilbert, Chloe Gaul, Joanne Webster, et al.
British Journal of Cancer|July 20, 2016
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC studySiân A Pugh, Megan Bowers, Alexandre Ball, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2024
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trialSomnath Mukherjee, Cathy Qi, Rachel Shaw, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2022
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP StudyJohn Bridgewater, Peter Fletcher, Daniel H Palmer, et al.
The Lancet. Gastroenterology & Hepatology|September 4, 2019
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trialNalinie Joharatnam-Hogan, Fay Cafferty, Richard Hubner, et al.
The Lancet. Oncology|May 7, 2025
Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trialAlexandra Gilbert, Richard Adams, Joanne Webster, et al.
The Lancet. Oncology|March 30, 2019
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 studyJohn N Primrose, Richard P Fox, Daniel H Palmer, et al.
The Lancet. Oncology|June 24, 2014
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, Paul Silcocks, Trevor Cox, et al.
The Lancet. Gastroenterology & Hepatology|September 21, 2023
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trialJohn V Reynolds, Shaun R Preston, Brian O'Neill, et al.
Pageof 6